ALPN News and Press, Alpine Immune Sciences Inc. From 05/19/21

- Alpine to hold Investor Event on Friday, June 4 at 7:00pm ET - - Program abstracts are now live on the ASCO website - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer a...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an oral presentation of preclinical data from the company’s ALPN-303 program at ...

Alpine Immune Sciences (ALPN): Q1 GAAP EPS of -$0.45 misses by $0.09.Revenue of $3.2M (+193.6% Y/Y) misses by $4.55M.Press Release For further details see: Alpine Immune Sciences EPS misses by $0.09, misses on revenue

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31,...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase 1 clinical trial of ALPN...

The strategic agreement with AbbVie for the development of ALPN-101 is the most valuable asset of the company. The recent share price decline can be attributed to several factors, including the expected announcement of ALPN-101 Phase 2 trail initiation and the associated AbbVie agreem...

– NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 costimulation – Alpine Immune Sciences, Inc. (NAS...

Image source: The Motley Fool. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) Q4 2020 Earnings Call Mar 18, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Call Tran...

Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Conference Call March 18, 2021 4:30 PM ET Company Participants Alex Sharif - Director, Investor Relations and Corporate Development Mitchell Gold - Executive Chairman and Chief Executive Officer Stanford Peng - President and Head of Researc...

Gainers: [[AAME]] +31.5%. [[MRKR]] +28.3%. [[KNSA]] +13.8%. [[WKEY]] +11.8%. [[SRPT]] +7.6%.Losers: [[PROG]] -6%. [[UPST]] -5.8%. [[ALPN]] -5.8%. [[SYBX]] -4.7%. [[ROAD]] -4.4%. For further details see: SRPT, UPST, MRKR and ALPN among after-hours movers